The impact of different CD4 cell-count monitoring and switching strategies on mortality in HIV-infected African adults on antiretroviral therapy: an application of dynamic marginal structural models

The impact of different CD4 cell-count monitoring and switching strategies on mortality in HIV-infected African adults on antiretroviral therapy: an application of dynamic marginal structural models

Taispeáin leaganacha eile (1)

In Africa, antiretroviral therapy (ART) is delivered with limited laboratory monitoring, often none. In 2003–2004, investigators in the Development of Antiretroviral Therapy in Africa (DART) Trial randomized persons initiating ART in Uganda and Zimbabwe to either laboratory and clinical monitoring (...

Cur síos iomlán

Sonraí bibleagrafaíochta
Príomhchruthaitheoirí:	Ford, D, Robins, JM, Petersen, ML, Gibb, DM, Gilks, CF, Mugyenyi, P, Grosskurth, H, Hakim, J, Katabira, E, Babiker, A, Walker, A
Formáid:	Journal article
Teanga:	English
Foilsithe / Cruthaithe:	Oxford University Press 2015

Míreanna comhchosúla

The Impact of Different CD4 Cell-Count Monitoring and Switching Strategies on Mortality in HIV-Infected African Adults on Antiretroviral Therapy: An Application of Dynamic Marginal Structural Models.
de réir: Ford, D, et al.
Foilsithe / Cruthaithe: (2015)

Daily co-trimoxazole prophylaxis in severely immunosuppressed HIV-infected adults in Africa started on combination antiretroviral therapy: an observational analysis of the DART cohort.
de réir: Walker, A, et al.
Foilsithe / Cruthaithe: (2010)

Impact of second-line antiretroviral regimens on lipid profiles in an African setting: the DART trial sub-study.
de réir: Gomo, Z, et al.
Foilsithe / Cruthaithe: (2014)

Prevalence, incidence and predictors of severe anaemia with zidovudine-containing regimens in African adults with HIV infection within the DART trial.
de réir: Ssali, F, et al.
Foilsithe / Cruthaithe: (2006)

Nevirapine/zidovudine/lamivudine has superior immunological and virological responses not reflected in clinical outcomes in a 48-week randomized comparison with abacavir/zidovudine/lamivudine in HIV-infected Ugandan adults with low CD4 cell counts.
de réir: Munderi, P, et al.
Foilsithe / Cruthaithe: (2010)

Mortality in the year following antiretroviral therapy initiation in HIV-infected adults and children in Uganda and Zimbabwe.
de réir: Walker, A, et al.
Foilsithe / Cruthaithe: (2012)

A single CD4 test with 250 cells/mm3 threshold predicts viral suppression in HIV-infected adults failing first-line therapy by clinical criteria
de réir: Gilks, C, et al.
Foilsithe / Cruthaithe: (2013)

Cost Effectiveness Analysis of Clinically Driven versus Routine Laboratory Monitoring of Antiretroviral Therapy in Uganda and Zimbabwe
de réir: Lara, A, et al.
Foilsithe / Cruthaithe: (2012)

Routine versus clinically driven laboratory monitoring of HIV antiretroviral therapy in Africa (DART): a randomised non-inferiority trial.
de réir: Mugyenyi, P, et al.
Foilsithe / Cruthaithe: (2010)

Cost effectiveness analysis of clinically driven versus routine laboratory monitoring of antiretroviral therapy in Uganda and Zimbabwe.
de réir: Antonieta Medina Lara, et al.
Foilsithe / Cruthaithe: (2012-01-01)

Glomerular dysfunction and associated risk factors over 4-5 years following antiretroviral therapy initiation in Africa.
de réir: Stöhr, W, et al.
Foilsithe / Cruthaithe: (2011)

High level of viral suppression and low switch rate to second-line antiretroviral therapy among HIV-infected adult patients followed over five years: retrospective analysis of the DART trial
de réir: Kityo, C, et al.
Foilsithe / Cruthaithe: (2014)

Changes over time in creatinine clearance and comparison of emergent adverse events for HIV-positive adults receiving standard doses (300 mg/day) of lamivudine-containing antiretroviral therapy with baseline creatinine clearance of 30-49 vs ≥50 mL/min
de réir: Ross, LL, et al.
Foilsithe / Cruthaithe: (2019)

Severe renal dysfunction and risk factors associated with renal impairment in HIV-infected adults in Africa initiating antiretroviral therapy.
de réir: Reid, A, et al.
Foilsithe / Cruthaithe: (2008)

Patterns of individual and population-level adherence to antiretroviral therapy and risk factors for poor adherence in the first year of the DART trial in Uganda and Zimbabwe.
de réir: Muyingo, S, et al.
Foilsithe / Cruthaithe: (2008)

DART and laboratory monitoring of HIV treatment Reply
de réir: Walker, A, et al.
Foilsithe / Cruthaithe: (2010)

Nevirapine clearance from plasma in African adults stopping therapy: a pharmacokinetic substudy.
de réir: Kikaire, B, et al.
Foilsithe / Cruthaithe: (2007)

Validation of World Health Organisation HIV/AIDS clinical staging in predicting initiation of antiretroviral therapy and clinical predictors of low CD4 cell count in Uganda.
de réir: Steven Baveewo, et al.
Foilsithe / Cruthaithe: (2011-01-01)

High level of viral suppression and low switch rate to second-line antiretroviral therapy among HIV-infected adult patients followed over five years: retrospective analysis of the DART trial.
de réir: Cissy Kityo, et al.
Foilsithe / Cruthaithe: (2014-01-01)

Marginal structural models for repeated measures where intercept and slope are correlated: an application exploring the benefit of nutritional supplements on weight gain in HIV-infected children initiating antiretroviral therapy
de réir: Farmer, R, et al.
Foilsithe / Cruthaithe: (2020)

Prevalence of lipodystrophy and metabolic abnormalities in HIV-infected African children after 3 years on first-line antiretroviral therapy.
de réir: Bwakura-Dangarembizi, M, et al.
Foilsithe / Cruthaithe: (2015)

Tuberculosis incidence is high in HIV-infected African children but is reduced by co-trimoxazole and time on antiretroviral therapy.
de réir: Crook, A, et al.
Foilsithe / Cruthaithe: (2016)

Changes over time in creatinine clearance and comparison of emergent adverse events for HIV-positive adults receiving standard doses (300 mg/day) of lamivudine-containing antiretroviral therapy with baseline creatinine clearance of 30-49 vs ≥50 mL/min.
de réir: Lisa L Ross, et al.
Foilsithe / Cruthaithe: (2019-01-01)

Monitoring of highly active antiretroviral therapy in HIV infection.
de réir: Walker, A, et al.
Foilsithe / Cruthaithe: (2011)

Pubertal development in HIV-infected African children on first-line antiretroviral therapy.
de réir: Szubert, A, et al.
Foilsithe / Cruthaithe: (2015)

Age and CD4 count at initiation of antiretroviral therapy in HIV-infected children: effects on long-term T-cell reconstitution.
de réir: Lewis, J, et al.
Foilsithe / Cruthaithe: (2012)

Highly active antiretroviral therapy started in infants under 3 months of age: 72-week follow-up for CD4 cell count, viral load and drug resistance outcome.
de réir: Aboulker, J, et al.
Foilsithe / Cruthaithe: (2004)

Antiretroviral regimens for preventing HIV infection in infants
de réir: René E. Ekpini, et al.
Foilsithe / Cruthaithe: (2005-07-01)

Enhanced prophylaxis with antiretroviral therapy for advanced HIV in Africa
de réir: Hakim, J, et al.
Foilsithe / Cruthaithe: (2017)

Thymic Output and CD4 T-Cell Reconstitution in HIV-Infected Children on Early and Interrupted Antiretroviral Treatment: Evidence from the Children with HIV Early Antiretroviral Therapy Trial
de réir: Lewis, J, et al.
Foilsithe / Cruthaithe: (2017)

Marginal structural models for repeated measures where intercept and slope are correlated: An application exploring the benefit of nutritional supplements on weight gain in HIV-infected children initiating antiretroviral therapy.
de réir: Ruth E Farmer, et al.
Foilsithe / Cruthaithe: (2020-01-01)

Virologic response to first-line efavirenz- or nevirapine-based antiretroviral therapy in HIV-infected African children
de réir: Kekitiinwa, A, et al.
Foilsithe / Cruthaithe: (2017)

Drug switching and virologic-based endpoints in trials of antiretroviral drugs for HIV infection.
de réir: Phillips, A, et al.
Foilsithe / Cruthaithe: (2004)

Antiretroviral treatment switch strategies for lowering the costs of antiretroviral therapy in subjects with suppressed HIV-1 viremia in Spain
de réir: Llibre JM, et al.
Foilsithe / Cruthaithe: (2013-05-01)

The impact of first year adherence to antiretroviral therapy on long-term clinical and immunological outcomes in the DART trial in Uganda and Zimbabwe.
de réir: Kiwuwa-Muyingo, S, et al.
Foilsithe / Cruthaithe: (2012)

The effect of AIDS defining conditions on immunological recovery among patients initiating antiretroviral therapy at Joint Clinical Research Centre, Uganda
de réir: Odere Mathew, et al.
Foilsithe / Cruthaithe: (2009-07-01)

Reduced bacterial skin infections in HIV-infected African children randomized to long-term cotrimoxazole prophylaxis
de réir: Prendergast, A, et al.
Foilsithe / Cruthaithe: (2016)

Evolution of antiretroviral phenotypic and genotypic drug resistance in antiretroviral-naive HIV-1-infected children treated with abacavir/lamivudine, zidovudine/lamivudine or abacavir/zidovudine, with or without nelfinavir (the PENTA 5 trial).
de réir: Gibb, D, et al.
Foilsithe / Cruthaithe: (2002)

Optimal CD4 count for initiating HIV treatment: impact of CD4 observation frequency and grace periods, and performance of dynamic marginal structural models.
de réir: Ewings, F, et al.
Foilsithe / Cruthaithe: (2014)

The impact of daily cotrimoxazole prophylaxis and antiretroviral therapy on mortality and hospital admissions in HIV-infected Zambian children.
de réir: Walker, A, et al.
Foilsithe / Cruthaithe: (2007)